692 related articles for article (PubMed ID: 28320445)
1. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients.
van den Brandt S; Zbinden A; Baeten D; Villiger PM; Østensen M; Förger F
Arthritis Res Ther; 2017 Mar; 19(1):64. PubMed ID: 28320445
[TBL] [Abstract][Full Text] [Related]
2. Maternal and Fetal Outcomes in a Cohort of Patients Exposed to Tumor Necrosis Factor Inhibitors throughout Pregnancy.
Genest G; Spitzer KA; Laskin CA
J Rheumatol; 2018 Aug; 45(8):1109-1115. PubMed ID: 29961692
[TBL] [Abstract][Full Text] [Related]
3. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
[TBL] [Abstract][Full Text] [Related]
4. Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.
Ciurea A; Exer P; Weber U; Tamborrini G; Steininger B; Kissling RO; Bernhard J; Scherer A;
Arthritis Res Ther; 2016 Mar; 18():71. PubMed ID: 27000865
[TBL] [Abstract][Full Text] [Related]
5. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
[TBL] [Abstract][Full Text] [Related]
6. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
[TBL] [Abstract][Full Text] [Related]
7. Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants.
Eworuke E; Panucci G; Goulding M; Neuner R; Toh S
Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):296-304. PubMed ID: 30430682
[TBL] [Abstract][Full Text] [Related]
8. Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial.
Ghiti Moghadam M; Vonkeman HE; Ten Klooster PM; Tekstra J; van Schaardenburg D; Starmans-Kool M; Brouwer E; Bos R; Lems WF; Colin EM; Allaart CF; Meek IL; Landewé R; Bernelot Moens HJ; van Riel PL; van de Laar MA; Jansen TL;
Arthritis Rheumatol; 2016 Aug; 68(8):1810-7. PubMed ID: 26866428
[TBL] [Abstract][Full Text] [Related]
9. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
[TBL] [Abstract][Full Text] [Related]
10. Poor efficacy of TNF inhibitors in non-radiographic axial spondyloarthritis in the absence of objective signs: A bicentric retrospective study.
Vidal C; Lukas C; Combe B; Berenbaum F; Pers YM; Jorgensen C; Sellam J; Morel J
Joint Bone Spine; 2018 Jul; 85(4):461-468. PubMed ID: 28917996
[TBL] [Abstract][Full Text] [Related]
11. Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
George MD; Baker JF; Ogdie A
J Rheumatol; 2020 Jun; 47(6):826-834. PubMed ID: 31474599
[TBL] [Abstract][Full Text] [Related]
12. Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors.
Lamers-Karnebeek FB; Luime JJ; Ten Cate DF; Teerenstra S; Swen NWAA; Gerards AH; Hendrikx J; van Rooyen EM; Voorneman R; Haagsma C; Basoski N; de Jager M; Ghiti Moghadam M; Efde MN; Goekoop-Ruiterman YPM; van Riel PLCM; Jacobs JWG; Jansen TL
Rheumatology (Oxford); 2017 Sep; 56(9):1560-1565. PubMed ID: 28595367
[TBL] [Abstract][Full Text] [Related]
13. Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
Michielsens CAJ; den Broeder N; Mulder MLM; van den Hoogen FHJ; Verhoef LM; den Broeder AA
Rheumatology (Oxford); 2022 May; 61(6):2307-2315. PubMed ID: 34599803
[TBL] [Abstract][Full Text] [Related]
14. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.
Micheroli R; Hebeisen M; Wildi LM; Exer P; Tamborrini G; Bernhard J; Möller B; Zufferey P; Nissen MJ; Scherer A; Ciurea A;
Arthritis Res Ther; 2017 Jul; 19(1):164. PubMed ID: 28724442
[TBL] [Abstract][Full Text] [Related]
15. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
[TBL] [Abstract][Full Text] [Related]
16. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study.
Park JW; Kim HA; Shin K; Park YB; Kim TH; Song YW; Lee EY
Arthritis Res Ther; 2019 Jul; 21(1):163. PubMed ID: 31272498
[TBL] [Abstract][Full Text] [Related]
17. Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.
Flouri I; Goutakoli P; Repa A; Bertsias A; Avgoustidis N; Eskitzis A; Pitsigavdaki S; Kalogiannaki E; Terizaki M; Bertsias G; Sidiropoulos P
Rheumatol Int; 2024 Feb; 44(2):249-261. PubMed ID: 37815625
[TBL] [Abstract][Full Text] [Related]
18. Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases.
Pombo-Suárez M; Seoane-Mato D; Díaz-González F; Sánchez-Alonso F; Sánchez-Jareño M; Cea-Calvo L; Castrejón I
Adv Rheumatol; 2023 Jun; 63(1):25. PubMed ID: 37287051
[TBL] [Abstract][Full Text] [Related]
19. Vasodilator function worsens after cessation of tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis only if a flare occurs.
Rongen GA; van Ingen I; Kok M; Vonkeman H; Janssen M; Jansen TL
Clin Rheumatol; 2018 Apr; 37(4):909-916. PubMed ID: 29307093
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial.
Bouman CA; van Herwaarden N; van den Hoogen FH; Fransen J; van Vollenhoven RF; Bijlsma JW; Maas AV; den Broeder AA
Ann Rheum Dis; 2017 Oct; 76(10):1716-1722. PubMed ID: 28606961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
